Guides, research, and insights from GLP
73 articlesFoundayo (orforglipron) was FDA-approved April 2026. Here's what to know before asking your doctor about this new oral GLP-1 pill — eligibility, dosing, clinical data, and smart
GLP-1 medications may reduce alcohol cravings and consumption. Here's what clinical trials, observational studies, and FDA data reveal — and what to tell your doctor.
GLP-1 prices vary dramatically by country. What personal importation rules actually say, the counterfeit risk in international sourcing, and why domestic alternatives usually make
GLP-1 medications aren't FDA-approved for type 1 diabetes but are used off-label for weight management. Research evidence, DKA safety considerations, and the specific management th
GLP-1 peptide medications require proper storage. Refrigeration rules, heat and freeze damage, travel best practices, and how to tell when a pen is no longer safe to use.
Post-operative GLP-1 resumption requires coordinating wound healing, nausea management, opioid interactions, and nutritional needs. The typical timeline by surgery type and practic
Exenatide-PD3 — the largest Phase 3 trial of a GLP-1 in Parkinson's disease — reported no benefit in February 2025. What it means for GLP-1 neuroprotection hopes and what trial
Social media and wellness commentary have created a folk understanding of GLP-1 medications that doesn't match the evidence. The 15 most common myths and what's actually true.
GLP-1 medications change the gut microbiome in patterns associated with metabolic health. What the research shows, what probiotics can and can't do, and why microbiome tests aren't
The compounding landscape changed dramatically in 2024-2025 after FDA removed semaglutide and tirzepatide from the shortage list. What's still legal, what isn't, and where patients
Wegovy pill was FDA approved December 2025 as the first oral GLP-1 for weight loss. OASIS 4 trial results, absorption rules, comparison with Foundayo, and who should consider switc
Facial changes during GLP-1 weight loss affect most patients over 40. What actually causes 'Ozempic face,' what prevention works, and what cosmetic options exist.
Some patients lose 30% of body weight on GLP-1 therapy; others lose almost nothing. What predicts response, why non-response happens, and the systematic approach to troubleshooting
GLP-1 medications are contraindicated during pregnancy. How to time the washout, handle weight regain during transition, and manage oral contraceptive absorption during titration.
Microdosing GLP-1 medications means different things to different people. What the term covers, which practices have evidence, and which are unsupported or unsafe.
Hair shedding on GLP-1 medications is telogen effluvium - temporary and reversible. The timeline, what causes it, what helps, and when to see a dermatologist.
The evoke and evoke+ trials are testing oral semaglutide for Alzheimer's disease. Why the connection exists, what the trials measure, and what a positive or negative result would m
CagriSema was filed with FDA in December 2025 for weight management. REDEFINE trial results, head-to-head with tirzepatide, and what this GLP-1/amylin combination might mean for pa
FDA approved Ozempic for CKD in type 2 diabetes in January 2025 based on the FLOW trial. 24% reduction in kidney disease progression, who qualifies, and how it combines with other
Every GLP-1 medication has a thyroid C-cell tumor warning. Where it came from, what human data shows after 20 years, and who absolutely should not take these medications.
GLP-1 medications in adults over 65 require specific considerations around sarcopenia, falls, polypharmacy, and function. What changes clinically and how to approach it safely.
In January 2026, the FDA officially removed the suicidal ideation warning from Wegovy, Zepbound, and Saxenda after reviewing 91 trials and 107,910 patients. What the evidence showe
GLP-1 medications are HSA/FSA eligible for diagnosed medical conditions. What documentation you need, how the tax math works, and the mistakes that cost the benefit.
Vial vs pen, LillyDirect vs retail, compounded vs branded — the complete 2026 pricing breakdown for Wegovy, Zepbound, and other GLP-1 medications.
GLP-1 medications make ordinary illness more complicated. When to skip doses, how to rehydrate, when to escalate to urgent care, and how to distinguish gastroenteritis from pancrea
GLP-1 medications after bariatric surgery can produce 10-15% additional weight loss in patients with regain. How the combination works, dosing considerations, and what to monitor.
Wegovy was FDA approved in March 2024 for cardiovascular risk reduction based on the SELECT trial. 20% MACE reduction, who qualifies, and why this opens new insurance pathways.
Wegovy was FDA approved for adolescents 12+ in December 2022. STEP-TEENS trial results, 2023 AAP guidelines, and how pediatric evaluation should work.
Perimenopause creates unique metabolic challenges. How GLP-1 medications work in this population, HRT coordination, and muscle/bone considerations.
Proper injection site rotation prevents lipohypertrophy and preserves drug absorption. Rotation patterns, recognizing problems, and when to call your provider.
GLP-1 medications for PCOS are off-label but increasingly used. What the research shows, how they compare to metformin, and how to plan around fertility.
GLP-1 constipation affects 24-44% of patients. The complete tiered protocol: water, fiber, magnesium, OTC options, and prescription strategies that actually work.
Food noise is a real neurological phenomenon. How GLP-1 medications quiet the brain's reward circuitry and default mode network to reduce food-related intrusive thoughts.
A 2025 RCT showed semaglutide reduced heavy drinking days in alcohol use disorder. What the evidence says, how the reward mechanism works, and the pancreatitis and hypoglycemia saf
Zepbound was FDA approved in December 2024 as the first medication ever for obstructive sleep apnea in adults with obesity. SURMOUNT-OSA data, eligibility, and how insurance covera
Wegovy received FDA approval in August 2025 for MASH with moderate-to-advanced liver fibrosis. ESSENCE trial data, who qualifies, and how it compares to resmetirom.
Complete travel guide for GLP-1 patients. TSA rules, keeping medication cold, time zone strategies, what to do if you miss a dose, and international travel considerations.
TRIUMPH-4 Phase 3 results showed 28.7% average weight loss with retatrutide at 68 weeks. How the triple agonist works, what's coming in 2026, and FDA approval timing.
20-40% of GLP-1 weight loss is lean mass. Protein targets, resistance training protocols, and age-specific strategies to preserve muscle during weight loss.
Weight loss stalls on GLP-1 at month 4-8 in most patients. Why the plateau happens, what actually breaks through it, and when to accept it as the end state.
ASA multi-society guidance on GLP-1 medications before surgery changed in 2024. What to hold, what to continue, and how to talk to your surgical team.
A 2026 Nature Health study used AI to analyze 410,000 Reddit posts and identified GLP-1 symptoms underreported in clinical trials. Clinical implications for prescribers and patient
Foundayo (orforglipron) was FDA approved April 1, 2026 as the first oral GLP-1 pill with no food or water timing rules. ATTAIN-1 data, dosing, pricing, and who it's for.
How to find an ABOM-certified obesity medicine specialist, when a specialist matters more than a generalist, and telehealth alternatives for areas with limited access.
Everything Medicare beneficiaries need to know about GLP-1 coverage in 2026 — the Bridge program, BALANCE Model, Part D redesign, and how to access Wegovy or Zepbound through Med
Free and discounted GLP-1 medication programs from Novo Nordisk, Eli Lilly, and independent organizations. Eligibility requirements, how to apply, and what to expect.
Which insurance plans cover GLP-1 medications for weight loss in 2026. Employer plans, marketplace coverage, Medicaid state-by-state, and how to check your formulary.
Every path to GLP-1 medication without insurance coverage. Manufacturer programs, compounded options, telehealth platforms, patient assistance, and clinical trials.
A plain-English guide to GLP-1 prior authorization. What triggers it, what your doctor submits, BMI thresholds by insurer, and how to avoid common denial traps.
GLP-1 medications aren't for everyone. An honest look at alternatives — metformin, Contrave, phentermine, bariatric surgery, and intensive lifestyle programs.
Step-by-step guide to NovoCare, LillyDirect, and other manufacturer savings programs for GLP-1 medications. Eligibility, pricing, and how to stack with insurance.
Step-by-step guide to appealing a GLP-1 insurance denial. Internal appeals, external reviews, peer-to-peer strategies, and the documentation that wins.
A clinical guide to switching between GLP-1 medications — semaglutide to tirzepatide or vice versa. Equivalent dosing, washout periods, and what to ask your doctor.
Critical drug interactions with GLP-1 medications including insulin, birth control, thyroid meds, and blood thinners. What your doctor and pharmacist need to know.
Why you can't start GLP-1 medication at the full dose. The clinical rationale behind titration schedules, how rushing causes dropout, and what to expect at each step.
A triage guide for GLP-1 side effects. When to call your doctor, when to go to the ER, and when you can safely wait it out.
Weight regain data, tapering protocols, maintenance strategies, and the conversation you need to have before stopping GLP-1 medication.
GLP-1 only vs dual GIP/GLP-1: mechanism differences, STEP vs SURMOUNT trial data, side effect profiles, and how doctors choose between semaglutide and tirzepatide.
Oral semaglutide vs injectable GLP-1: absorption requirements, efficacy differences, convenience, and which patients benefit most from each format.
What to expect as your GLP-1 dose increases month by month. Titration schedules for semaglutide and tirzepatide, plateau management, and when your doctor should hold or increase.
Your first month on GLP-1 medication: what side effects are normal, how to manage nausea, what to eat, and when something needs medical attention.
A1C, kidney function, liver enzymes, lipids, thyroid — the lab tests your doctor should order during GLP-1 treatment and how often.
A step-by-step walkthrough of what actually happens during a GLP-1 telehealth consultation — from the intake quiz to getting your medication shipped.
LegitScript verification, state licensing lookup, compounding pharmacy accreditation, and 12 red flags that signal an unsafe GLP-1 provider.
Your GLP-1 provider should ask about thyroid history, current meds, pregnancy, and more. Here are 10 questions that separate quality care from prescription mills.
Should you see your doctor in person or use telehealth for GLP-1? An honest look at the advantages and limitations of each approach.
Checklist for your first GLP-1 appointment: medical records, medication list, weight history, insurance info, and questions to ask.
How thyroid history, pancreatitis, kidney disease, pregnancy, and other conditions affect your GLP-1 eligibility. What a thorough screening looks like.
FDA-approved vs compounded GLP-1 medications: what they are, how they differ, regulatory status in 2026, and questions to ask your provider.
Calculate your BMI for GLP-1 eligibility. Plus: why BMI alone doesn't tell the full picture and what else your doctor should consider.
Scripts, strategies, and tips for bringing up GLP-1 weight loss medication with your doctor. What to say and what to expect.
BMI requirements, qualifying conditions, and disqualifiers for GLP-1 weight loss medication. Find out if you're eligible.
Your doctor said no to GLP-1 medication. Here are your next steps: second opinions, telehealth providers, and alternative paths.
No articles found matching your search.